Experimental virus therapy takes on Drug-Resistant lung cancer
NCT ID NCT06125197
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that delivers immune-boosting signals directly into tumors, with the immunotherapy drug pembrolizumab. The study aims to find a safe dose and check for side effects in about 22 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TILT-123 (a modified virus that delivers immune-boosting proteins) combined with pembrolizumab (an immunotherapy drug)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced lung cancer whose current immunotherapy has stopped working.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, not yet on effectiveness. The virus may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92658, United States
-
UCLA Jonsson Comprehensive Cancer Center
Santa Monica, California, 90404, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?